
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Pregabalin | FAERS: 7 | US FAERS | |
| 2 | Dimethyl Fumarate | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 3 | Tiotropium Bromide | FAERS: 2 | US FAERS | |
| 4 | 5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol | FAERS: 1 | US FAERS | |
| 5 | Albuterol | FAERS: 1 | US FAERS | |
| 6 | Albuterol | FAERS: 1 | US FAERS | |
| 7 | Aripiprazole | FAERS: 1 | US FAERS | |
| 8 | Dabigatran | FAERS: 1 | US FAERS | |
| 9 | Dichlorphenamide | FAERS: 1 | US FAERS | |
| 10 | Esomeprazole | FAERS: 1 | US FAERS | |
| 11 | Fingolimod Hydrochloride | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 12 | LCZ 696 | FAERS: 1 | US FAERS | |
| 13 | Naltrexone | FAERS: 1 | US FAERS | |
| 14 | Piroxicam | FAERS: 1 | US FAERS | |
| 15 | Rivaroxaban | FAERS: 1 | US FAERS | |
| 16 | Teriparatide | FAERS: 1 | US FAERS | |
| 17 | apixaban | FAERS: 1 | US FAERS | |
| 18 | apremilast | FAERS: 1 | US FAERS | |
| 19 | bosutinib | FAERS: 1 | US FAERS | |
| 20 | regadenoson | FAERS: 1 | US FAERS | |
| 21 | teriflunomide | FAERS: 1 | US FAERS | |
| 22 | tofacitinib | FAERS: 1 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 23 | treprostinil | FAERS: 1 | US FAERS | |
| 24 | Ezetimibe | Canada Vigilance: 1 | Canada Vigilance | |
| 25 | Methadone | 16089243 | CTD | |
| 26 | Methylprednisolone Acetate | 10414580 | CTD | |
| 27 | Octreotide | Canada Vigilance: 1 | Canada Vigilance | |
| 28 | Triamcinolone | 10414580 | CTD | |
| 29 | Warfarin | Canada Vigilance: 1 | Canada Vigilance | |
| 30 | Zoledronic Acid | Canada Vigilance: 5 | Canada Vigilance | |
| 31 | lamivudine, zidovudine drug combination | Canada Vigilance: 1 | Canada Vigilance |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120237
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.